← Back to Search

Cytokine

CYT107 for Coronavirus (ILIAD-7-BRA Trial)

Phase 2
Waitlist Available
Led By Reinaldo SALOMAO, MD
Research Sponsored by Revimmune
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one month
Awards & highlights

Summary

Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

Eligible Conditions
  • Coronavirus
  • Lymphocytopenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Body Weight Changes
Secondary study objectives
All-cause mortality through day 45 compared to placebo arm
CD8-Positive T-Lymphocytes
Frequency of re-hospitalization through day 45 compared to placebo arm
+11 more
Other study objectives
Safety assessment through incidence and scoring of grade 3-4 adverse events

Side effects data

From 2018 Phase 2 trial • 27 Patients • NCT02640807
44%
Injection site reaction
33%
Hepatic cytolysis
33%
High alkaline phosphatase
22%
Gastrointestinal bleed
22%
Anemia
22%
High potassium
22%
Persisting Fever
22%
Vomiting
22%
Acute hypoxic event
22%
Deep Vein Thrombosis
22%
High sodium
22%
Supra ventricular tachycardia
22%
Ascites
22%
Renal failure
22%
Ileus
22%
Low phosphate
11%
Tracheobronchitis
11%
Mediastinitis
11%
Cutaneous rash
11%
Confusion
11%
Weaning failure
11%
Hypoglycemia
11%
Lung Abscess
11%
Papilledema
11%
Tamponade
11%
Relapse of endocarditis
11%
Oesophago-bronchial fistula
11%
Ischemic stroke
11%
Bile leak
11%
ischemic colitis
11%
Diarrhea
11%
Yeast infection
11%
Skin erosion
11%
Low Calcium
11%
DRESS
11%
Acute respiratory failure
11%
Pleural effusion
11%
Dyspepsia
11%
Dysphagia
11%
Depression
11%
Intra-abdominal collections
11%
Ischemic Colitis
11%
Recurrent septic shock
11%
Epistaxis
11%
Oral herpes
11%
Urinary infection
11%
Necrotizing fingers
11%
Cholestatis
11%
Acute renal failure
11%
Ventricular tachycardia
11%
Hypercapnic coma
11%
Endocarditis
11%
Hemorrhagic gastric ulcer
11%
Ileopsoas hematoma
11%
Pressure ulcer
100%
80%
60%
40%
20%
0%
Study treatment Arm
CYT107 High Frequency
CYT107 Low Frequency
Control

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CYT107Experimental Treatment1 Intervention
IM administration of CYT107 / Interleukin-7
Group II: PLACEBOPlacebo Group1 Intervention
IM administration of Saline at the same volume
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Interleukin-7
2016
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

C.R.O. ReSolution Latin America S.A.UNKNOWN
RevimmuneLead Sponsor
10 Previous Clinical Trials
207 Total Patients Enrolled
ReSolution Latin America S.A.UNKNOWN
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top